Vicore Management

Carl-Johan Dalsgaard has been a Venture Partner at HealthCap since 2000, thereby he has served as CEO of several companies in which HealthCap has invested. Prior to that, he has ten years of experience from senior positions within the AstraZeneca Group, such as pre-clinical research director, therapeutic area manager of pain and anesthesia, CEO of Astra Pain Control AB and part of the Group’s research management team.

Shareholdings: 477,981

Options: 400,000

Education: MD from the Karolinska Institute. PhD in neurobiology and post-doc experience from Harvard Medical School. Carl-Johan Dalsgaard has also completed a specialist training in plastic surgery.

Hans Jeppsson has a cross-disciplinary background in finance and medicine. He has previously worked as a biotech analyst at Danske Bank as well as within preclinical research at AstraZeneca R&D.

Shareholdings: 5,000

Options: 250,000

Education: Ph.D. in Strategic Financial Management from the University of Gothenburg. After he obtained his Ph.D.-degree he conducted postdoctoral studies at the Haas School of Business at the UC Berkeley in the US. He also has a background in chemical engineering with a focus on biotechnology from Chalmers University of Technology.

Elin Rosendahl has more than 20 years’ experience of managing global biopharmaceutical development programs and leading cross-functional teams. Solid experience of all phases of clinical drug development with focus on design of innovative and patient-focused paths to market, effective management of global, cross-functional teams and optimized collaborations with contract research organizations (CROs)

Shareholdings: –

Options: 100,000

Education: M.Sc, Pharmacy from Uppsala University

Rohit Batta has over 20 years of experience as a medical doctor with an extensive background leading medical and clinical development teams whilst developing drugs for rare diseases. His previous roles include senior level positions within Cell and Gene Therapy at GlaxoSmithKline leading the clinical development and defining the clinical strategy for haemoglobinopathy gene therapy medicines. He also led the global medical and late stage clinical development teams to launch the world’s first gene therapy for patients with a paediatric rare disease. Rohit holds an MBBS from Kings College London where he is currently a Senior Visiting Lecturer

Shareholdings: –

Options: 200,000

Education: MBBS from Kings College London and is a member of the Royal College of General Practitioners and the Faculty of Pharmaceutical Medicine.

Johan Raud has more than 20 years of experience from heading research teams and managing drug discovery projects in both big pharma and startups. Johan gained his MD, PhD and Associate Professorship at Karolinska Institutet and Vanderbilt University.

Shareholdings: 238,991

Options: 130,000

Education: MD PhD from the Karolinska Institute and Vanderbilt university, USA

Johanna has a Ph.D and expertise in pharmaceutical metabolism. She has extensive experience in preclinical interpretation and is responsible for drug development projects.

Shareholding: 7 004

Options: 143,750

Education: MSc PhD

Jessica Shull has more than 20 years’ experience in the field of digital technologies for healthcare including development of virtual surgical devices. She is considered an authority in HTA requirements for patient-facing software and innovation adoption in Europe and internationally. In previous roles she worked on digital health best practices for the WHO and with the Digital Therapeutics Alliance she focused on digital therapeutic product integration, regulation, and policy.

Shareholdings: –

Options: – 50,000

Education: MA, MSc, PhD candidate Biomedicine 2022

Nina has more than 20 years experience of working with communication and administration in the medical industry.

Shareholding: 24 480
Options: 175,000

Åsa Magnusson has more than 20 years of experience as a commercial executive in the pharmaceutical industry with focus on securing market access and launching rare disease medicines. Her previous roles include leading cross-functional teams as General Manager at Arvelle and in different senior commercial roles at Alexion, expanding innovative antibody products and heading the commercial launch of Actelion’s pulmonary arterial hypertension (PAH) pharmaceuticals.

Shareholdings: –

Options: 50.000

Education: BBA and B2B marketing from Lund University

Mikael Nygård has extensive experience from Business Development in the healthcare industry. He has led M&A and Corporate Development at the care provider Humana AB and has also worked in the global healthcare team at the strategy consulting firm Boston Consulting Group.

Shareholdings: –

Options: 41.000

Education: MSc Pharmacy, Uppsala University. PhD Neurobiology, Karolinska Institutet.